The company's activities range from drug discovery to early-stage clinical trials and they have a pipeline of bi-specific antibodies and small molecules that have an enhanced immuno-stimulatory activity in the tumor microenvironment for efficient tumor eradication. In addition, they have bispecific Fc-fusions that inhibit the alternative complement pathway while inhibiting angiogenesis and downstream complement activation for autoimmune diseases. Kanaph Therapeutics aims to enhance patient response rates for immuno-oncology drugs by overcoming immune suppression in the tumor microenvironment, providing researchers and doctors with a better fit for the treatment of cancer.